Recent studies by the Advanced Technologies and Treatments for Diabetes consensus on CGM and the ADA and European Association for the Study of Diabetes consensus on precision medicine in diabetes found that although the use of CGMs offers an opportunity to use high-frequency data to identify deteriorating glucose control and tailor personalized management strategies, no standardized, validated methods currently exist outside of automated insulin delivery systems [4,14]. The gene discussed is INS; the disease is diabetes mellitus.